<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Vaxart Inc’s (NASDAQ: VXRT) has disclosed data from a 12-subject Phase 1b blinded study evaluating the ability of its oral norovirus vaccine to boost immunogenicity. Study participants were initially vaccinated with Vaxart’s oral norovirus vaccine in late 2019 and were vaccinated again between February and April 2021.
...read full article on Benzinga
